ARTICLE | Company News
Nereus other research news
October 29, 2001 8:00 AM UTC
Nereus received a 3-year Phase I/II SBIR grant for up to $850,000 from the National Institute of Allergy and Infectious Diseases to develop its NPI-1302a-3 oral inhibitor of TNF-alpha and interleukin...